FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079746058> ?p ?o ?g. }

• W2079746058 endingPage "99" @default.
• W2079746058 startingPage "93" @default.
• W2079746058 abstract "Purpose: Although concomitant radiation therapy (RT) and bolus 5-Fluorouracil (5-FU) have been shown to improve survival in locally confined pancreatic cancer, most patients will eventually succumb to their disease. Since 1994, we have attempted to improve efficacy by administering 5-FU as a protracted venous infusion (PVI). This study compares treatment intensity and acute toxicity of consecutive protocols of concurrent RT and 5-FU by bolus injection or PVI.Methods and Materials: Since 1986, 74 patients with resected or locally advanced pancreatic cancer were treated with continuous course RT and concurrent 5-FU by bolus injection (n = 44) or PVI throughout the course of RT (n = 30). Dose intensity was assessed for both 5-FU and radiotherapy. Toxicity endpoints which could be reliably and objectively quantified (e.g., neutropenia, weight loss, treatment interruption) were evaluated.Results: Cumulative 5-FU dose (mean = 7.2 vs. 2.5 gm/m2, p < 0.001) and weekly 5-FU dose (mean = 1.3 vs. 0.5 gm/m2/wk, p < 0.001) were significantly higher for patients receiving PVI 5-FU. Following pancreaticoduodenectomy, 95% of PVI patients maintained a RT dose intensity of ≥ 900 cGy/wk, compared with 63% of those receiving bolus 5-FU (p = 0.02). No difference was seen for patients with locally advanced disease (72% vs. 76%, p = n.s.). Grade II-III neutropenia was less common for patients treated with PVI (13% vs. 34%, p = 0.05). Grade II-III thrombocytopenia was uncommon (≤ 3%) in both treatment groups. Mean percent weight loss (3.8% vs. 4.1%, p = n.s.) and weight loss ≥ 5% of pre-treatment weight (21% vs. 31%, p = n.s.) were similar for PVI and bolus treatment groups, respectively. Treatment interruptions for hematologic, gastrointestinal or other acute toxicities were less common for patients receiving PVI 5-FU (10% vs. 25%, p = 0.11).Conclusion: Concurrent RT and 5-FU by PVI was well tolerated and permitted greater chemotherapy and radiotherapy dose intensity with reduced hematologic toxicity and fewer treatment interruptions compared with RT and bolus 5-FU. Longer follow-up will be needed to assess late effects and the impact on overall survival." @default.
• W2079746058 created "2016-06-24" @default.
• W2079746058 creator A5000851669 @default.
• W2079746058 creator A5015083055 @default.
• W2079746058 creator A5027563495 @default.
• W2079746058 creator A5030963552 @default.
• W2079746058 creator A5036188351 @default.
• W2079746058 creator A5041427302 @default.
• W2079746058 creator A5055511966 @default.
• W2079746058 creator A5061896844 @default.
• W2079746058 creator A5070367602 @default.
• W2079746058 creator A5073269496 @default.
• W2079746058 creator A5078629816 @default.
• W2079746058 creator A5089159861 @default.
• W2079746058 date "1998-01-01" @default.
• W2079746058 modified "2023-10-14" @default.
• W2079746058 title "Chemo-Radiotherapy For Localized Pancreatic Cancer: Increased Dose Intensity and Reduced Acute Toxicity with Concomitant Radiotherapy and Protracted Venous Infusion 5-Fluorouracil" @default.
• W2079746058 cites W1763850369 @default.
• W2079746058 cites W1902766545 @default.
• W2079746058 cites W1926559864 @default.
• W2079746058 cites W1965404729 @default.
• W2079746058 cites W1981928698 @default.
• W2079746058 cites W1985600290 @default.
• W2079746058 cites W1987870343 @default.
• W2079746058 cites W1989407605 @default.
• W2079746058 cites W2002734622 @default.
• W2079746058 cites W2016236483 @default.
• W2079746058 cites W2021324583 @default.
• W2079746058 cites W2030955710 @default.
• W2079746058 cites W2045659020 @default.
• W2079746058 cites W2055983050 @default.
• W2079746058 cites W2058600799 @default.
• W2079746058 cites W2080080319 @default.
• W2079746058 cites W2095507740 @default.
• W2079746058 cites W2131728068 @default.
• W2079746058 cites W2135352785 @default.
• W2079746058 cites W2150881991 @default.
• W2079746058 cites W2152292894 @default.
• W2079746058 cites W2171422837 @default.
• W2079746058 cites W2265021315 @default.
• W2079746058 cites W2323577539 @default.
• W2079746058 cites W4237434210 @default.
• W2079746058 cites W4362046093 @default.
• W2079746058 doi "https://doi.org/10.1016/s0360-3016(97)00493-8" @default.
• W2079746058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9422563" @default.
• W2079746058 hasPublicationYear "1998" @default.
• W2079746058 type Work @default.
• W2079746058 sameAs 2079746058 @default.
• W2079746058 citedByCount "46" @default.
• W2079746058 countsByYear W20797460582014 @default.
• W2079746058 countsByYear W20797460582015 @default.
• W2079746058 crossrefType "journal-article" @default.
• W2079746058 hasAuthorship W2079746058A5000851669 @default.
• W2079746058 hasAuthorship W2079746058A5015083055 @default.
• W2079746058 hasAuthorship W2079746058A5027563495 @default.
• W2079746058 hasAuthorship W2079746058A5030963552 @default.
• W2079746058 hasAuthorship W2079746058A5036188351 @default.
• W2079746058 hasAuthorship W2079746058A5041427302 @default.
• W2079746058 hasAuthorship W2079746058A5055511966 @default.
• W2079746058 hasAuthorship W2079746058A5061896844 @default.
• W2079746058 hasAuthorship W2079746058A5070367602 @default.
• W2079746058 hasAuthorship W2079746058A5073269496 @default.
• W2079746058 hasAuthorship W2079746058A5078629816 @default.
• W2079746058 hasAuthorship W2079746058A5089159861 @default.
• W2079746058 hasBestOaLocation W20797460581 @default.
• W2079746058 hasConcept C121608353 @default.
• W2079746058 hasConcept C126322002 @default.
• W2079746058 hasConcept C126894567 @default.
• W2079746058 hasConcept C141071460 @default.
• W2079746058 hasConcept C151032500 @default.
• W2079746058 hasConcept C2776694085 @default.
• W2079746058 hasConcept C2777063308 @default.
• W2079746058 hasConcept C2779384505 @default.
• W2079746058 hasConcept C2780210213 @default.
• W2079746058 hasConcept C2780456651 @default.
• W2079746058 hasConcept C29730261 @default.
• W2079746058 hasConcept C43376680 @default.
• W2079746058 hasConcept C509974204 @default.
• W2079746058 hasConcept C71924100 @default.
• W2079746058 hasConcept C90924648 @default.
• W2079746058 hasConceptScore W2079746058C121608353 @default.
• W2079746058 hasConceptScore W2079746058C126322002 @default.
• W2079746058 hasConceptScore W2079746058C126894567 @default.
• W2079746058 hasConceptScore W2079746058C141071460 @default.
• W2079746058 hasConceptScore W2079746058C151032500 @default.
• W2079746058 hasConceptScore W2079746058C2776694085 @default.
• W2079746058 hasConceptScore W2079746058C2777063308 @default.
• W2079746058 hasConceptScore W2079746058C2779384505 @default.
• W2079746058 hasConceptScore W2079746058C2780210213 @default.
• W2079746058 hasConceptScore W2079746058C2780456651 @default.
• W2079746058 hasConceptScore W2079746058C29730261 @default.
• W2079746058 hasConceptScore W2079746058C43376680 @default.
• W2079746058 hasConceptScore W2079746058C509974204 @default.
• W2079746058 hasConceptScore W2079746058C71924100 @default.
• W2079746058 hasConceptScore W2079746058C90924648 @default.
• W2079746058 hasIssue "1" @default.
• W2079746058 hasLocation W20797460581 @default.
• W2079746058 hasLocation W20797460582 @default.

• next